Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures

Brivaracetam (BRV), a high-affinity synaptic vesicle protein 2A ligand, reported to be 10–30-fold more potent than levetiracetam (LEV), is highly effective in a wide range of experimental models of focal and generalized seizures. BRV and LEV similarly bind to synaptic vesicle protein 2A, while diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mumoli, Laura, Palleria, Caterina, Gasparini, Sara, Citraro, Rita, Labate, Angelo, Ferlazzo, Edoardo, Gambardella, Antonio, De Sarro, Giovambattista, Russo, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622453/
https://www.ncbi.nlm.nih.gov/pubmed/26543353
http://dx.doi.org/10.2147/DDDT.S81474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622453/
https://www.ncbi.nlm.nih.gov/pubmed/26543353
http://dx.doi.org/10.2147/DDDT.S81474

Ejemplares similares